Redwood AI Corp. (CSE: AIRX)(OTCQB: RDWCF)(Frankfurt: Y0N, WKN: A422EZ), a developer of artificial intelligence-powered chemical synthesis technology, announced the addition of Chemical AI Risk Evaluator (CARE) to its Reactosphere platform. CARE is a reaction-safety screening and decision-support feature designed to help chemists identify potential safety concerns earlier in the synthesis planning process.
CARE consolidates Safety Data Sheet (SDS) information, Globally Harmonized System (GHS) hazard indicators, structural alerts, and reaction-specific safety findings into a single profile. The feature incorporates a custom, chemist-curated rule framework to evaluate chemical identities, reagent and condition combinations, and potential reaction hazards, providing severity assessments and recommendations for further review. CARE also integrates with Reactosphere’s retrosynthesis workflow, enabling users to compare proposed synthetic routes based on potential safety risks, flagged chemicals, and required review efforts. Safety profiles can be exported as PDF documents for recordkeeping and further evaluation.
The company said the addition strengthens Reactosphere’s capabilities in chemical synthesis planning and safety-aware decision support across multiple industries. CARE is intended as a preliminary screening tool and does not replace qualified chemist or environmental, health and safety review before operational use.
For investors, the announcement signals continued product development by Redwood AI Corp., which is developing AI and cybersecurity solutions for defense, public safety, and life sciences. The company’s technology aims to help organizations prepare for quantum-enabled cybersecurity threats while enabling faster development of new therapies and chemistry-driven applications. More details are available in the full press release at https://ibn.fm/8pjGL, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/RDWCF.
The news was disseminated through TinyGems, a communications platform focused on small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. For full terms and disclaimers, visit https://www.TinyGems.com/Disclaimer.
The introduction of CARE matters because safety screening is a critical step in chemical synthesis, and early identification of hazards can reduce risks and improve efficiency. By integrating safety assessments into the retrosynthesis workflow, Redwood AI aims to provide chemists with a tool that supports safer decision-making. However, the company emphasizes that CARE is a preliminary screening tool and should not replace professional review. This development could enhance productivity in industries reliant on chemical synthesis, such as pharmaceuticals and materials science, by enabling faster and more informed route selection.
